Mirabegron

Mirabegron (trade name Myrbetriq in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.

Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.

Medical uses

Its primary use is in the treatment of overactive bladder. Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation. Recently, mirabegron was shown to relax in vitro human and rabbit prostate smooth muscle through activation of beta3-adrenoceptor. The same group also showed that mirabegron promotes smooth muscle relaxation by alpha1-adrenoceptor blockade.

Adverse effects

Adverse effects by incidence:

Very common (>10% incidence) adverse effects include: